Emily Ferguson Elevated to Sr. Director, HR Business Partner at Alnylam Pharmaceuticals

Emily Ferguson has been promoted to Senior Director, HR Business Partner for Development & Medical Affairs at Alnylam Pharmaceuticals, marking a significant milestone in her career. This promotion, effective from April 2024, comes after a year of impactful contributions to Alnylam’s U.S. and Global Commercial operations.

Since joining Alnylam in May 2023, Ferguson has swiftly ascended from Director to Senior Director, underscoring her vital role and expertise within the organization. In her new capacity, Ferguson will continue to drive strategic HR initiatives, focusing on aligning HR operations with the firm’s ambitious goals in development and medical affairs.

Prior to her tenure at Alnylam, Ferguson amassed extensive experience at Alexion Pharmaceuticals, where she led as Director, People & Culture for the U.S. Commercial sector. Here, she was a key member of the U.S. Leadership Team, responsible for spearheading performance management, culture change, and executive coaching initiatives. Ferguson’s strategic vision significantly enhanced organizational dynamics and positioned her as a leader adept at navigating complex corporate landscapes.

Her foundational experiences include roles at JPMorgan Chase & Co., where she developed a keen acumen for talent management and diversity, and Liberty Mutual Insurance, where she supported corporate development programs and leadership training initiatives. Ferguson’s cumulative expertise encompasses a broad spectrum of HR disciplines, including strategic planning, conflict resolution, and cross-functional team leadership, which have been instrumental in her rapid career progression.

About Alnylam Pharmaceuticals:

Alnylam Pharmaceuticals is a pioneer in RNA interference (RNAi) therapeutics, leading the charge in developing innovative treatments for rare genetic, cardio-metabolic, hepatic, CNS, and ocular diseases. Founded in 2002, based on Nobel Prize-winning research, Alnylam was the first company to achieve market approval for an RNAi therapeutic with the launch of ONPATTRO in 2018. With a robust pipeline and four additional medicines on the market, Alnylam is dedicated to transforming scientific possibilities into clinical realities. Headquartered in Cambridge, Massachusetts, and extending its reach globally, Alnylam continues to be recognized as a top employer and innovator in the biopharmaceutical sector.